AC
APLS

Aristeia Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Aristeia Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-11,600
Closed -$279K – 57
2019
Q3 		$279K Buy
+11,600
New +$319K 0.02% 59

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Aristeia Capital's APLS Position: Q4 2019 in Review

Aristeia Capital sold out of Apellis Pharmaceuticals (APLS) in Q4 2019, closing a stake of 11,600 shares — an estimated $279K sold.

Aristeia Capital first reported a position in APLS in Q3 2019 and held it in 1 quarter. The position peaked at $279K in Q3 2019. 133 funds tracked by Wall St. Rank hold APLS as of Q4 2019.

  • Aristeia Capital reported no remaining Apellis Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Aristeia Capital sold 11,600 Apellis Pharmaceuticals shares in Q4 2019, an estimated $279K.
  • Aristeia Capital first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Aristeia Capital's Apellis Pharmaceuticals position peaked at $279K in Q3 2019.
  • 133 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2019.

Based on Aristeia Capital's 13F filing for Q4 2019, filed 18 Feb 2020.